Few studies have attempted to adapt BRD4 inhibitors to treat ovarian cancer cells [17,18,33,34,35], and most of them have focused on the relationship between PARP inhibitors and BET inhibitors or the correlation between BRD4 expression and basic function in ovarian cancer [18,33,34]. The gene discussed is DNER; the disease is ovarian carcinoma.